How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-thromboembolism-with-chronic-atrial-fibrillation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of Thromboembolism with Chronic Atrial Fibrillation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Thromboembolism with Chronic Atrial Fibrillation (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Thromboembolism with Chronic Atrial Fibrillation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Pradaxa	dabigatran-etexilate	Boehringer Ingelheim	Direct thrombin inhibitor	Thrombin (serine protease)	2010-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Dabigatran etexilate (DE)	dabigatran-etexilate-de	Pfizer Inc.	Dabigatran etexilate (DE) as oral capsule	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 1 drug in Prevention of Thromboembolism with Chronic Atrial Fibrillation
Generic (originally Boehringer Ingelheim) · 1 drug in Prevention of Thromboembolism with Chronic Atrial Fibrillation
Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Prevention of Thromboembolism with Chronic Atrial Fibrillation
Pfizer Inc. · 1 drug in Prevention of Thromboembolism with Chronic Atrial Fibrillation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Thromboembolism with Chronic Atrial Fibrillation:

Cite this brief

Drug Landscape (2026). Prevention of Thromboembolism with Chronic Atrial Fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-thromboembolism-with-chronic-atrial-fibrillation. Accessed 2026-06-10.

Prevention of Thromboembolism with Chronic Atrial Fibrillation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing